Millie Das, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Das’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A92503 · Current
Licensed to practise in California · since 2005 · expires 2027-08-31 · University of Massachusetts Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$21,617
Medicare paid this office $21,617 for 50 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 32 | $8,431 | $119 |
| Return visit (30+ min) | 20 | $3,977 | $80 |
Who their Medicare patients are
50 Original Medicare patients in 2024. Average age 76 · Women 56% · Also on Medicaid 32% · Health risk score 2.50. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 75% · High blood pressure 74% · Coronary heart disease 32% · Diabetes 28% · Chronic kidney disease 26% · COPD 24% · Depression 22%.
The office billed $93,765, Medicare allowed $28,549 and paid $21,617; for 183 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 50 | 183 | 76 | 2.50 | $93,765 | $21,617 |
| 2023 | 46 | 185 | 75 | 2.17 | $100,107 | $19,254 |
| 2022 | 46 | 187 | 74 | 2.05 | $100,717 | $19,089 |
| 2021 | 49 | 176 | 74 | 2.24 | $95,370 | $19,131 |
| 2020 | 28 | 117 | 74 | 2.46 | $37,965 | $9,614 |
| 2019 | 21 | 101 | 71 | 2.57 | $12,221 | $8,478 |
| 2018 | 27 | 113 | 72 | 2.86 | $11,579 | $8,178 |
| 2017 | 29 | 126 | 72 | 2.81 | $22,787 | $9,107 |
| 2016 | 31 | 134 | 73 | 2.40 | $29,548 | $10,397 |
| 2015 | 32 | 107 | 75 | 1.72 | $26,254 | $9,230 |
| 2014 | 25 | 78 | 74 | 2.08 | $19,491 | $6,073 |
| 2013 | 33 | 142 | 74 | 1.99 | $30,764 | $10,452 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 34 | $10,067 | $87 |
| Long return visit (40+ min) | 12 | $6,782 | $130 |
| New patient visit (60+ min) | 14 | $2,171 | $155 |
2022: 3 services
| Return visit (30+ min) | 36 | $10,291 | $87 |
| Long return visit (40+ min) | 13 | $6,250 | $120 |
| New patient visit (60+ min) | 16 | $2,487 | $155 |
2021: 3 services
| Return visit (30+ min) | 28 | $10,013 | $90 |
| Long return visit (40+ min) | 14 | $5,330 | $133 |
| New patient visit (60+ min) | 23 | $3,591 | $156 |
2020: 2 services
| Return visit (30+ min) | 20 | $4,807 | $69 |
| New patient visit (60+ min) | 11 | $1,578 | $143 |
2019: 1 service
| Return visit (30+ min) | 14 | $4,647 | $68 |
2018: 1 service
| Return visit (30+ min) | 19 | $6,755 | $66 |
2017: 2 services
| Return visit (30+ min) | 19 | $7,236 | $66 |
| New patient visit (60+ min) | 13 | $1,667 | $128 |
2016: 2 services
| Return visit (30+ min) | 22 | $8,048 | $69 |
| New patient visit (60+ min) | 17 | $2,349 | $138 |
2015: 2 services
| Return visit (30+ min) | 19 | $5,625 | $69 |
| New patient visit (60+ min) | 22 | $3,226 | $147 |
2014: 2 services
| Return visit (30+ min) | 12 | $3,974 | $64 |
| New patient visit (60+ min) | 13 | $1,944 | $150 |
2013: 2 services
| Return visit (30+ min) | 27 | $8,243 | $65 |
| New patient visit (60+ min) | 16 | $2,210 | $138 |
Money from drug and device companies
$47,811 in 2025
| 2025 | 15 | 58 | $44,240 | $47,811 |
| 2024 | 14 | 54 | $28,449 | $31,558 |
| 2023 | 13 | 54 | $29,719 | $34,300 |
| 2022 | 6 | 11 | $8,543 | $9,167 |
| 2021 | 3 | 6 | $17,116 | $17,116 |
| 2020 | 2 | 3 | $6,355 | $6,370 |
| 2019 | 2 | 4 | $5,233 | $5,361 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Zepzelca | $14,239 | 13 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $9,545 | 10 payments
|
| Eli Lilly and | None | $5,200 | 2 payments
|
| Janssen Biotech | Rybrevant | $3,576 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $3,553 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $3,475 | 1 payment
|
See all 58 published payments
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-16 | Enhertu | $2,870 |
| Eli Lilly and | Consulting · 2025-12-10 | None | $2,400 |
| Eli Lilly and | Consulting · 2025-12-10 | None | $2,800 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-05 | Enhertu | $126 |
| Regeneron Healthcare Solutions | Meals · 2025-11-24 | Libtayo | $41 |
| Regeneron Healthcare Solutions | Meals · 2025-11-24 | Libtayo | $70 |
| Regeneron Healthcare Solutions | Meals · 2025-11-24 | Libtayo | $26 |
| Genentech | Meals · 2025-10-16 | Tecentriq | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | None | $135 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-10-08 | Tagrisso | $4,510 |
| Daiichi Sankyo | Meals · 2025-09-20 | Enhertu | $116 |
| Daiichi Sankyo | Meals · 2025-09-08 | Datroway | $20 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-09-02 | None | $3,553 |
| Abbvie | Consulting · 2025-08-05 | None | $600 |
| Abbvie | Meals · 2025-07-26 | Emrelis | $45 |
| Daiichi Sankyo | Meals · 2025-07-25 | Enhertu | $44 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-25 | None | $99 |
| Janssen Biotech | Meals · 2025-07-24 | Rybrevant | $45 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-24 | None | $31 |
| EMD Serono | Meals · 2025-07-24 | None | $52 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-07-14 | None | $3,475 |
| Genentech USA | Meals · 2025-06-25 | Alecensa | $120 |
| Genentech USA | Consulting · 2025-06-25 | Alecensa | $2,050 |
| Janssen Biotech | Consulting · 2025-06-24 | Rybrevant | $1,500 |
| Janssen Biotech | Travel · 2025-06-24 | Rybrevant | $474 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-06-24 | Zepzelca | $8,850 |
| Jazz Pharmaceuticals | Travel · 2025-06-24 | Zepzelca | $134 |
| Jazz Pharmaceuticals | Meals · 2025-06-24 | Zepzelca | $37 |
| Jazz Pharmaceuticals | Meals · 2025-06-24 | Zepzelca | $19 |
| Jazz Pharmaceuticals | Meals · 2025-06-24 | Zepzelca | $8 |
| Jazz Pharmaceuticals | Meals · 2025-06-14 | Zepzelca | $98 |
| Jazz Pharmaceuticals | Meals · 2025-06-14 | Zepzelca | $68 |
| Jazz Pharmaceuticals | Travel · 2025-06-13 | Zepzelca | $275 |
| Jazz Pharmaceuticals | Meals · 2025-06-13 | Zepzelca | $147 |
| Genentech USA | Meals · 2025-06-01 | None | $68 |
| Daiichi Sankyo | Meals · 2025-05-31 | Enhertu | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-31 | Tagrisso | $53 |
| Jazz Pharmaceuticals | Meals · 2025-05-31 | Zepzelca | $123 |
| Janssen Biotech | Meals · 2025-05-30 | Rybrevant | $57 |
| Genentech | Meals · 2025-05-30 | Tecentriq | $29 |
| Jazz Pharmaceuticals | Travel · 2025-04-16 | Zepzelca | $248 |
| Jazz Pharmaceuticals | Travel · 2025-04-16 | Zepzelca | $248 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-04-15 | None | $1,640 |
| Daiichi Sankyo | Meals · 2025-04-12 | Enhertu | $28 |
| Janssen Biotech | Consulting · 2025-04-10 | Rybrevant | $1,500 |
| Gilead Sciences | Consulting · 2025-04-08 | Trodelvy | $760 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | Imfinzi | $60 |
| Daiichi Sankyo | Meals · 2025-02-20 | Enhertu | $32 |
| Jazz Pharmaceuticals | Paid to speak or teach · 2025-02-18 | Zepzelca | $3,983 |
| Catalyst Pharmaceuticals | Honoraria · 2025-02-10 | Firdapse | $750 |
| Genentech USA | Meals · 2025-02-01 | Tecentriq | $110 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-25 | None | $21 |
| Genentech | Meals · 2025-01-24 | Tecentriq | $62 |
| Partner Therapeutics | Travel · 2025-01-09 | Bizengri | $83 |
| Partner Therapeutics | Consulting · 2025-01-09 | Bizengri | $3,000 |
| Partner Therapeutics | Travel · 2025-01-09 | Bizengri | $7 |
| Partner Therapeutics | Travel · 2025-01-09 | Bizengri | $35 |
| Partner Therapeutics | Travel · 2025-01-09 | Bizengri | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $31,558
| Janssen Biotech | Rybrevant | $7,406 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $6,093 | 5 payments
|
| Abbvie | None | $5,441 | 2 payments
|
| Novocure | Optune Lua (Novottf-200t) | $5,369 | 4 payments
|
| EMD Serono | None | $3,325 | 1 payment
|
| Daiichi Sankyo | Enhertu | $1,040 | 8 payments
|
| Partner Therapeutics | None | $918 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $828 | 13 payments
|
| Gilead Sciences | Trodelvy | $760 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $176 | 2 payments
|
| Genentech USA | Alecensa | $102 | 2 payments
|
| Genentech | None | $45 | 1 payment
|
| Amgen | None | $39 | 1 payment
|
| ADC Therapeutics America | None | $18 | 1 payment
|
2023: $34,300
| Novocure | None | $12,720 | 20 payments
|
| E.R. Squibb & Sons L.L.C. | None | $5,613 | 5 payments
|
| Regeneron Healthcare Solutions | Libtayo | $3,370 | 4 payments
|
| Regeneron Pharmaceuticals | Libtayo | $2,996 | 2 payments
|
| Gilead Sciences | Trodelvy | $2,708 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $2,192 | 4 payments
|
| Catalyst Pharmaceuticals | Firdapse | $1,663 | 2 payments
|
| Bristol Myers Squibb | None | $1,288 | 1 payment
|
| Genzyme | None | $1,149 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $229 | 2 payments
|
| Genentech USA | None | $138 | 1 payment
|
| Daiichi Sankyo | Enhertu | $124 | 3 payments
|
| Genentech | Alecensa | $111 | 2 payments
|
2022: $9,167
| AstraZeneca UK | None | $3,768 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $3,661 | 4 payments
|
| Janssen Scientific Affairs | Rybrevant | $1,350 | 1 payment
|
| Genentech | Tecentriq | $174 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $161 | 2 payments
|
| Zap Surgical Systems | Zap-X Mv Imager | $54 | 1 payment
|
2021: $17,116
| Genzyme | Libtayo | $9,157 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $6,508 | 2 payments
|
| BeiGene | None | $1,452 | 1 payment
|
2020: $6,370
| Jazz Pharmaceuticals | Zepzelca | $6,355 | 2 payments
|
| Novartis Pharmaceuticals | Ilaris | $15 | 1 payment
|
2019: $5,361
| AstraZeneca Pharmaceuticals LP | Imfinzi | $5,233 | 3 payments
|
| Genentech USA | None | $128 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Placebo-Controlled Clinical Study To Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy Sbrt With Or Without Pembrolizumab Mk-3475 in Participants With Unresected Stage I Or II Non-Small Cell Lung Cancer Nsclc Keynote-867 · 2024 | Their institution | $132,509 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Placebo-Controlled Clinical Study To Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy Sbrt With Or Without Pembrolizumab Mk-3475 in Participants With Unresected Stage I Or II Non-Small Cell Lung Cancer Nsclc Keynote-867 · 2023 | Their institution | $123,578 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Placebo-Controlled Clinical Study To Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy Sbrt With Or Without Pembrolizumab Mk-3475 in Participants With Unresected Stage I Or II Non-Small Cell Lung Cancer Nsclc Keynote-867 · 2022 | Their institution | $43,103 |
| AbbVie, Inc. · 2019 | Their institution | $40,238 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2022 | Their institution | $18,635 |
| Genentech, Inc. · 1lm Sclc Tecentriq Lurbinectedin · 2022 | Their institution | $16,636 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2021 | Their institution | $13,517 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2020 | Their institution | $12,322 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Placebo-Controlled Clinical Study To Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy Sbrt With Or Without Pembrolizumab Mk-3475 in Participants With Unresected Stage I Or II Non-Small Cell Lung Cancer Nsclc · 2025 | Their institution | $10,642 |
| United Therapeutics Corporation · A Two-Part Open-Label Randomized Phase Iiiii Study of Dinutuximab and Irinotecan Versus Irinotecan for Second-Line Treatment of Subjects With Relapsed Or Refractory Small Cell Lung Cancer · 2019 | Their institution | $10,315 |
| Genentech, Inc. · 1lm Sclc Tecentriq Lurbinectedin · 2024 | Their institution | $5,912 |
| United Therapeutics Corporation · A Two-Part Open-Label Randomized Phase II/III Study of Dinutuximab and Irinotecan Versus Irinotecan for Second-Line Treatment of Subjects With Relapsed Or Refractory Small Cell Lung Cancer · 2020 | Their institution | $5,511 |
| Genentech, Inc. · 1lm Sclc Tecentriq Lurbinectedin · 2023 | Their institution | $5,000 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2023 | Their institution | $4,300 |
| AbbVie Inc. · 2020 | Their institution | $4,125 |
| Celgene Corporation · A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study To Evaluate Nab-Paclitaxel (Abraxane®) As Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (Nsclc) (Abi-007-Nscl-003) · 2019 | Their institution | $2,500 |
| Amgen Inc. · P3 2l Sclc 2-Arm Mono 757 Vs Soc . · 2024 | Their institution | $1,301 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2019 | Their institution | $12 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225182322
- Licence
- CA A92503California A92503: Current · expires 2027-08-31
- Trained
- University of Massachusetts Medical School, 2004
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-23
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.